Document Detail


Activation of ANP synthesis during congestive heart failure in rats treated with monocrotaline.
MedLine Citation:
PMID:  7840289     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We studied plasma concentration, content, and mRNA for atrial natriuretic peptide (ANP-mRNA) in heart chambers of monocrotaline-treated rats. Three distinct groups emerged: group 1, with moderate congestive heart failure (CHF; pleural effusion < 1 ml; no peritoneal effusion); group 2, with severe CHF (pleural and peritoneal effusion > 1 ml); and group 3, with right hypertrophy and no CHF. Group 1 and 2 rats had right atrial and ventricular hypertrophy, raised plasma ANP (from 16.31 +/- 11.32 to 98.50 +/- 22.50 and 124.09 +/- 57.29 pg/ml, respectively; P < 0.001), and depletion of right atrial ANP (from 143.23 +/- 29.79 to 21.70 +/- 17.70 and 18.12 +/- 14.64 nmol/g, respectively; P < 0.001). Ventricular ANP concentration was unchanged. ANP-mRNA rose in the right atrium [10.6 (P < 0.02) and 7.9 (P < 0.01) times] and right ventricle (53.0 and 46.6 times; P < 0.01). In left unhypertrophied chambers it also increased, although to a smaller extent. Group 3 rats had isolated right ventricular hypertrophy, normal ANP levels in plasma and tissues, and no activation of synthesis. These data suggest that 1) plasma concentration and ANP synthesis are increased only in animals with CHF, 2) activation of ANP synthesis is maximal in early stages of CHF and is not related to the degree of hypertrophy, and 3) ANP-mRNA is also expressed in unhypertrophied heart chambers of rats with CHF but is not expressed in hypertrophied chambers of animals without CHF.
Authors:
L Comini; G Agnoletti; A Panzali; G Mantero; E Pasini; G Gaia; A Albertini; R Ferrari
Related Documents :
17498579 - Admission b-type natriuretic peptide levels and in-hospital mortality in acute decompen...
20447539 - The prognostic value of n-terminal pro-b-type natriuretic peptide for death and cardiov...
19789399 - Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular ar...
11129679 - Clinical significance of brain natriuretic peptide in patients with postmyocardial infa...
15635209 - Predictors of mortality in patients with acute myocardial infarction and cardiogenic sh...
19804159 - Current and future uses of nesiritide.
10947919 - Stent thrombosis: historical perspectives and current trends.
3973519 - Non-transmural infarction: clinical distinction between patients with st depression and...
8782149 - Psoriatic spondyloarthropathy with secondary amyloidosis.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of physiology     Volume:  268     ISSN:  0002-9513     ISO Abbreviation:  Am. J. Physiol.     Publication Date:  1995 Jan 
Date Detail:
Created Date:  1995-02-27     Completed Date:  1995-02-27     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0370511     Medline TA:  Am J Physiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  H391-8     Citation Subset:  IM    
Affiliation:
Fondazione Clinica del Lavoro, Centro di Fisiopatologia Cardiovascolare Salvatore Maugeri, Gussago, Brescia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Ascitic Fluid
Atrial Natriuretic Factor / biosynthesis*
Cardiomegaly / metabolism,  physiopathology
Female
Gene Expression / drug effects*
Heart Failure / metabolism*,  physiopathology*
Hypertrophy, Right Ventricular / metabolism,  physiopathology
Monocrotaline / pharmacology*
Myocardium / metabolism*
Organ Specificity
Pleural Effusion
RNA, Messenger / biosynthesis
Rats
Rats, Sprague-Dawley
Chemical
Reg. No./Substance:
0/RNA, Messenger; 315-22-0/Monocrotaline; 85637-73-6/Atrial Natriuretic Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Facilitated ventriculoatrial conduction: effects of sequential pacing interval and basic cycle lengt...
Next Document:  Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells.